Nasdaq:SKIN
Beauty Health Co
Beauty Health Co. delivers premium skincare and wellness products through a hybrid direct-to-consumer and retail distribution model.
Key Metrics
Investment Thesis
Bull Case
Despite recent revenue contraction and losses, the company holds a substantial cash position relative to its liabilities and maintains a dominant market share in niche premium skincare categories. If the company can successfully optimize its cost structure and reverse the revenue decline, the current valuation could present an attractive entry point for long-term growth investors.
Bear Case
The stock faces severe headwinds from a widening retained earnings deficit of -$508.0M and negative operating profit of -$67.8M, which signals deep structural inefficiencies or high customer acquisition costs. With revenue falling year-over-year and cash flow turning negative, the company risks dilution through equity issuance to cover losses rather than organic growth.
About Beauty Health Co
Beauty Health Co. (NASDAQ: SKIN) is a premier provider of premium skincare products and wellness solutions targeting the global beauty market. The company leverages a direct-to-consumer model alongside strategic retail partnerships to distribute its innovative portfolio of serums, creams, and supplements. With a diverse product range and strong digital presence, SKIN aims to capture growth in the expanding personal care sector.
Analysis
Management Discussion
While revenue contracted to $334.3M in 2024 from a 2023 peak of $398.0M, the company continues to operate at a net loss of $29.1M, reflecting substantial operating expenses of $250.1M against gross profits of $182.3M. Cash reserves have decreased significantly year-over-year due to financing outflows and negative cash flow from operations, suggesting a need for improved profitability or cost management.
Industry Overview
The global skincare industry is experiencing robust expansion driven by increasing consumer focus on wellness and personalized beauty solutions, yet it remains highly competitive with low barriers to entry for generic products. Beauty Health Co. must differentiate itself through innovation and brand loyalty to maintain margins in this crowded marketplace.
Financial Statements
Income Statement
Balance Sheet
Cash Flow
| Metric | 2022 | 2023 | 2024 |
|---|---|---|---|
| Revenue | $365.9M | $398.0M | $334.3M |
| Cost of Revenue | $115.5M | $242.9M | $152.0M |
| Gross Profit | $250.3M | $155.1M | $182.3M |
| Operating Expenses | $274.6M | $286.0M | $250.1M |
| Operating Income | $-24.3M | $-130.9M | $-67.8M |
| R&D | $8.4M | $10.1M | $6.3M |
| G&A | $106.1M | $131.4M | $125.5M |
| Marketing | $160.1M | $144.5M | $118.3M |
| Stock-Based Comp | $28.5M | $22.5M | $26.7M |
| Depreciation | $7.2M | $11.3M | $9.9M |
| Amortization | $14.9M | $20.9M | $19.5M |
| Other OpEx | $0 | $0 | $0 |
| Non-Operating Income | $69.3M | $29.0M | $38.2M |
| Interest Expense | — | $13.6M | — |
| Interest Income | $9.2M | $23.2M | $16.6M |
| Pre-Tax Income | $45.0M | $-101.9M | $-29.6M |
| Income Tax | $648.0K | $-1.8M | $-452.0K |
| Continuing Ops | $44.4M | $-100.1M | $-29.1M |
| Discontinued Ops | $0 | $0 | $0 |
| Net Income | $44.4M | $-100.1M | $-29.1M |
| Minority Interest | $0 | $0 | $0 |
| Net to Common | $44.4M | $-100.1M | $-29.1M |
| Metric | 2022 | 2023 | 2024 |
|---|---|---|---|
| Current Assets | $789.1M | $698.3M | $477.1M |
| Cash & Equivalents | $568.2M | $523.0M | — |
| Accounts Receivable | $76.5M | $54.7M | $27.6M |
| Inventory | $116.4M | $91.3M | $69.1M |
| Prepaid Expenses | $26.7M | $28.9M | $9.5M |
| Other Current Assets | $1.3M | $332.0K | $370.9M |
| Long-Term Assets | $219.8M | $230.9M | $208.6M |
| Goodwill | $124.6M | $125.8M | $123.5M |
| Operating Leases | $15.6M | $12.1M | $13.6M |
| Other LT Assets | $79.6M | $92.9M | $71.5M |
| Total Assets | $1.01B | $929.1M | $685.7M |
| Current Liabilities | $73.1M | $115.0M | $68.2M |
| Accounts Payable | $30.3M | $44.8M | $21.9M |
| Current Leases | $5.0M | $4.6M | $5.1M |
| Deferred Revenue | — | — | $2.4M |
| Taxes Payable | $962.0K | $2.8M | $3.4M |
| Other Current Liab | $21.7M | $43.0M | $15.3M |
| Long-Term Liabilities | $764.3M | $754.7M | $565.7M |
| LT Operating Leases | $12.7M | $9.3M | $10.8M |
| Other LT Liab | $751.6M | $745.4M | $554.9M |
| Total Liabilities | $837.4M | $869.7M | $633.9M |
| Shareholders' Equity | $171.5M | $59.4M | $51.8M |
| Paid-In Capital | $550.3M | $541.3M | $566.7M |
| Retained Earnings | $-374.3M | $-478.9M | $-508.0M |
| AOCI | $-4.5M | $-3.0M | $-7.0M |
| Total L&E | $1.01B | $929.1M | $685.7M |
| Metric | 2022 | 2023 | 2024 |
|---|---|---|---|
| Net Income (CFO) | $44.4M | $-100.1M | $-29.1M |
| Non-Cash Adjustments | $-280.1M | $57.2M | $105.4M |
| Working Capital Changes | $129.1M | $64.6M | $-60.2M |
| Cash from Operations | $-106.6M | $21.8M | $16.1M |
| Capital Expenditures | $10.8M | $3.8M | $756.0K |
| Cash from Investing | $-18.9M | $-31.5M | $-6.8M |
| Share Buybacks | $160.0M | $30.2M | $0 |
| Cash from Financing | $-205.2M | $-37.4M | $-158.3M |
| FX Effect | $-3.0M | $2.0M | $-4.0M |
| Net Change in Cash | $-330.7M | $-47.2M | $-149.0M |
| Beginning Cash | $901.9M | $568.2M | $523.0M |
| Ending Cash | $568.2M | $523.0M | $370.1M |
Frequently Asked Questions
How does Beauty Health Co make money?
The company generates revenue primarily through its proprietary high-margin skincare lines sold via e-commerce platforms and select retail partners, supplemented by lower-margin wholesale arrangements and strategic licensing agreements for brand extensions.
What are the main risks for SKIN?
Investors should monitor the company's significant leverage with current liabilities exceeding current assets, the recurring net losses indicating potential product margin or cost structure issues, high sensitivity to shifts in consumer discretionary spending, and regulatory complexities associated with global skincare compliance.
What is SKIN's competitive advantage?
SKIN benefits from strong brand equity in the premium beauty segment, a highly engaged direct-to-consumer customer base that allows for higher gross margins, and a robust intellectual property portfolio of patented formulations and proprietary delivery systems.
Related Companies
Not financial advice. All content is for informational purposes only. Data may contain errors. Consult a qualified financial advisor before making investment decisions.